Outcomes of IncobotulinumtoxinA Injection on Myalgia and Arthralgia in Patients Undergoing Temporomandibular Joint Arthroscopy: A Randomized Controlled Trial
Toxins · 2023
DOI: 10.3390/toxins15060376 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Toxins, 2023. Verfasst von David Faustino Ângelo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Instituto Português da Face, 1050-227 Lisboa, Portugal. Hauptthemen laut MEDLINE: Arthralgia, Botulinum Toxins, Type A, Myalgia, Temporomandibular Joint Disorders. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The present study was funded by Merz Pharmaceuticals GmbH.
Abstract (Originalsprache)
Background
Several studies have considered Botulinum Neurotoxin Type A injections effective in treating temporomandibular joint disorder (TMD) symptoms. A double-blind, randomized, controlled clinical trial investigated the benefit of complementary incobotulinumtoxinA (inco-BoNT/A) injections in the masticatory muscles of patients submitted to bilateral temporomandibular joint (TMJ) arthroscopy.
Methods
Fifteen patients with TMD and an indication for bilateral TMJ arthroscopy were randomized into inco-BoNT/A (Xeomin, 100 U) or placebo groups (saline solution). Injections were carried out five days before TMJ arthroscopy. The primary outcome variable was a Visual Analogue Scale for TMJ arthralgia, and secondary outcomes were the myalgia degree, maximum mouth opening, and joint clicks. All outcome variables were assessed preoperatively (T0) and postoperatively (T1—week 5; T2—6-month follow-up).
Results
At T1, the outcomes in the inco-BoNT/A group were improved, but not significantly more than in the placebo group. At T2, significant improvements in the TMJ arthralgia and myalgia scores were observed in the inco-BoNT/A group compared to the placebo. A higher number of postoperative reinterventions with further TMJ treatments were observed in the placebo group compared to inco-BoNT/A (63% vs. 14%).
Conclusions
In patients submitted to TMJ arthroscopy, statistically significant long-term differences were observed between the placebo and inco-BoNT/A groups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Instituto Português da Face, 1050-227 Lisboa, Portugal.
- Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisboa, Portugal.
- Centre for Rapid and Sustainable Product Development, Polytechnic Institute of Leiria, 2430-028 Marinha Grande, Portugal.
- Clínica Universitária de Estomatologia, Centro Hospitalar Universitário Lisboa Norte-Hospital de Santa Maria, 1649-028 Lisboa, Portugal.
- Maxillofacial Surgery Unit, Department of Neurosciences, Reproductive and Odontostomatological Sciences, University of Naples "Federico II", Via Sergio Pansini 5, 80131 Naples, Italy.
ORCID-Profile: David Faustino Ângelo, Francesco Maffia, Henrique José Cardoso
Förderung
- The present study was funded by Merz Pharmaceuticals GmbH
Zitieren
APA
Ângelo, D. F., Sanz, D., Maffia, F., & Cardoso, H. J. (2023). Outcomes of IncobotulinumtoxinA Injection on Myalgia and Arthralgia in Patients Undergoing Temporomandibular Joint Arthroscopy: A Randomized Controlled Trial. Toxins. https://doi.org/10.3390/toxins15060376
Vancouver
Ângelo DF, Sanz D, Maffia F, Cardoso HJ. Outcomes of IncobotulinumtoxinA Injection on Myalgia and Arthralgia in Patients Undergoing Temporomandibular Joint Arthroscopy: A Randomized Controlled Trial. Toxins. 2023. doi:10.3390/toxins15060376
BibTeX
@article{ngelo2023,
author = {Ângelo, David Faustino and Sanz, David and Maffia, Francesco and Cardoso, Henrique José},
title = {Outcomes of IncobotulinumtoxinA Injection on Myalgia and Arthralgia in Patients Undergoing Temporomandibular Joint Arthroscopy: A Randomized Controlled Trial},
journal = {Toxins},
year = {2023},
doi = {10.3390/toxins15060376}
}
EUVIMED